**Supplementary Table S1. Prevalence and Comparison of Generalized Anxiety Disorder Mutually Exclusive Groups By Sociodemographic Characteristics**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **GAD Mutually Exclusive Definition** | | | **Comparisons of**  **Mutually Exclusive GAD Groups** | |
|  | **Weighted Prevalence % SE** | | | **Adjusted Odds Ratio (95% CI)** | |
|  | **GAD-6mo**  **n = 284** | **GAD-3-5mo**  **n = 179** | **GAD-3-5mo/**  **NOU**  **n = 214** | **GAD-3-5mo**  **vs.**  **GAD-6mo** | **GAD-3-5mo/**  **NOU**  **vs.**  **GAD-6mo** |
| **Total** | 3.03 (0.38) | 2.00 (0.23) | 2.43 (0.23) | **--** | **--** |
| **Sex** |  |  |  |  |  |
| Male | 1.86 (0.32) | 1.42 (0.27) | 2.01 (0.27) | 1.00 | 1.00 |
| Female | 4.25(0.67) | 2.60 (0.45) | 2.87 (0.47) | 0.81 (0.38-1.73) | 0.63 (0.33-1.21) |
| Wald χ21 (*p*) | -- | -- | -- | 0.29 (0.5913) | 1.93 (0.1652) |
| **Age** |  |  |  |  |  |
| 13-14 years | 1.36 (0.36) | 1.29 (0.22) | 1.59 (0.24) | 1.00 | 1.00 |
| 15-16 years | 3.75 (0.62) | 2.36 (0.44) | 2.87 (0.42) | 0.74 (0.33-1.70) | 0.75 (0.35-1.61) |
| 17-18 years | 4.37 (0.56) | 2.46 (0.46) | 2.95 (0.54) | 0.63 (0.29-1.40) | 0.62 (0.28-1.36) |
| Wald χ22 (*p*) | -- | -- | -- | 0.29 (0.5913) | 1.57 (0.4552) |
| **Race/Ethnicity** |  |  |  |  |  |
| Non-Hispanic White | 3.54 (0.50) | 1.95 (0.30) | 2.34 (0.32) | 1.00 | 1.00 |
| Hispanic | 1.86 (0.40) | 1.81 (0.43) | 2.13 (0.35) | 1.67 (0.86-3.25) | 1.54 (0.83-2.84) |
| Non-Hispanic Black | 2.70 (0.59) | 2.24 (0.54) | 2.75 (0.61) | 1.49 (0.63-3.53) | 1.45 (0.63-3.33) |
| Other | 1.74 (0.30) | 2.46 (1.07) | 3.43 (1.10) | 2.78 (1.08-7.18) | 3.21 (1.52-6.77) |
| Wald χ23 (*p*) |  |  |  | 8.17 (0.0427) | 10.90 (0.0123) |
| **Poverty Index Ratio** |  |  |  |  |  |
| > 6 | 2.73 (0.42) | 2.24 (0.45) | 2.69 (0.46) | 1.00 | 1.00 |
| ≤ 6 | 3.68 (0.56) | 2.21 (0.36) | 2.50 (0.42) | 0.72 (0.37-1.43) | 0.70 (0.36-1.38) |
| ≤ 3 | 3.15 (0.82) | 1.45 (0.28) | 1.84 (0.36) | 0.48 (0.22-1.03) | 0.49 (0.24-1.00) |
| ≤ 1.5 | 2.14 (0.50) | 1.67 (0.48) | 2.42 (0.55) | 0.83 (0.31-2.27) | 1.06 (0.41-2.72) |
| Wald χ23 (*p*) |  |  |  | 3.65 (0.3013) | 4.28 (0.2325) |

Note. GAD = generalized anxiety disorder; GAD-6mo = cases met DSM-IV/5 GAD criteria; GAD-3-5mo = duration

was **≥**3 months and **<** 6 months; GAD-3-5mo/NOU = duration was **≥**3 months and **<** 6 months and uncontrollability

criterion was not applied; CI = confidence interval; adjusted odds ratios and 95% confidence intervals include all sociodemographic predictors.

**Supplementary Table S2. Associated Symptoms and Course Characteristics Across Generalized Anxiety Disorder Mutually Exclusive Groups**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **GAD Mutually Exclusive Definition** | | | **Comparisons of**  **Mutually Exclusive GAD Groups** | |
|  | **Weighted Proportion % SE** | | | **Adjusted Odds Ratio (95% CI)** | |
| **Associated Symptoms** | **GAD-6mo**  **n = 284** | **GAD-3-5mo**  **n = 179** | **GAD-3-5mo/**  **NOU**  **n = 214** | **GAD-3-5mo**  **vs.**  **GAD-6mo** | **GAD-3-5mo/**  **NOU**  **vs.**  **GAD-6mo** |
| Restlessness, % (SE) | 71.30 (4.42) | 85.16 (3.06) | 79.75 (3.64) | 3.00 (1.54-5.85) | 1.98 (0.99-4.00) |
| Wald χ21 (*p*) |  |  |  | 10.33 (0.0013) | 3.68 (0.0551) |
| Easily Fatigued, % (SE) | 55.78 (3.46) | 60.65 (5.86) | 60.48 (6.14) | 1.25 (0.67-2.31) | 1.30 (0.70-2.42) |
| Wald χ21 (*p*) |  |  |  | 0.49 (0.4846) | 0.68 (0.4097) |
| Poor Concentration, % (SE) | 83.41 (3.05) | 84.60 (4.03) | 84.48 (3.44) | 1.10 (0.46-2.63) | 1.06 (0.48-2.35) |
| Wald χ21 (*p*) |  |  |  | 0.04 (0.8355) | 0.02 (0.8939) |
| Irritable, % (SE) | 71.51(4.16) | 74.94 (4.17) | 69.04 (4.20) | 1.37 (0.66-2.83) | 1.07 (0.54-2.12) |
| Wald χ21 (*p*) |  |  |  | 0.71 (0.3998) | 0.04 (0.8467) |
| Muscle Tension, % (SE) | 46.74 (3.47) | 46.25 (4.21) | 41.67 (3.59) | 1.07 (0.60-1.93) | 0.94 (0.55-1.60) |
| Wald χ21 (*p*) |  |  |  | 0.05 (0.8166) | 0.05 (0.8162) |
| Sleep Disturbance, % (SE) | 70.05 (3.04) | 62.56 (2.68) | 66.06 (3.62) | 1.02 (0.65-1.60) | 0.86 (0.54-1.35) |
| Wald χ21 (*p*) |  |  |  | 0.01 (0.9405) | 0.46 (0.4972) |
| Either Restless or Muscle Tension, % (SE) | 77.83 (3.47) | 89.80 (1.96) | 85.86 (2.89) | 2.92 (1.59-5.37) | 2.02 (1.06-3.85) |
| Wald χ21 (*p*) |  |  |  | 11.85 (0.0006) | 4.52 (0.0336) |
| One Symptom, % (SE) | 6.93 (2.61) | 2.72 (1.15) | 2.71 (1.13) | 0.32 (0.08-1.20) | 0.35 (0.11-1.08) |
| Wald χ21 (*p*) |  |  |  | 2.85 (0.0911) | 3.36 (0.0666) |
| Two Symptoms, % (SE) | 12.34 (2.36) | 14.07 (3.51) | 20.54 (3.96) | 1.13 (0.50-2.54) | 1.74 (0.83-3.65) |
| Wald χ21 (*p*) |  |  |  | 0.09 (0.7655) | 2.18 (0.1398) |
| Three Symptoms, % (SE) | 13.74 (3.06) | 14.63 (3.82) | 13.59 (3.55) | 0.97 (0.43-2.16) | 0.82 (0.34-1.95) |
| Wald χ21 (*p*) |  |  |  | 0.01 (0.9303) | 0.21 (0.6482) |
| Four Symptoms, % (SE) | 28.76 (4.81) | 20.06 (3.16) | 19.32 (3.16) | 0.58 (0.31-1.08) | 0.54 (0.30-1.00) |
| Wald χ21 (*p*) |  |  |  | 2.96 (0.0854) | 3.84 (0.0500) |
| Five Symptoms, % (SE) | 17.39 (2.65) | 23.82 (3.61) | 22.04 (4.12) | 1.67 (0.86-3.25) | 1.58 (0.77-3.23) |
| Wald χ21 (*p*) |  |  |  | 2.25 (0.1340) | 1.58 (0.2092) |
| Six Symptoms, % (SE) | 19.65 (3.08) | 24.45 (4.62) | 21.41 (4.11) | 1.44 (0.69-3.03) | 1.30 (0.63-2.68) |
| Wald χ21 (*p*) |  |  |  | 0.95 (0.3308) | 0.51 (0.4757) |
| Number of Symptoms, *M* (SE) | 3.97 (0.14) | 4.22 (0.18) | 4.02 (0.17) | --- | --- |
| Wald *F*1 (*p*) |  |  |  | 0.18 (0.6730) | 0.07 (0.7947) |
| **Course Characteristics** |  |  |  |  |  |
| Age At Onset (years), *Md* (SE) | 11.83 (0.35) | 12.14 (0.28) | 12.25 (0.30) | --- | --- |
| Wald χ21 (*p*) |  |  |  | 1253.77(<0.0001) | 4282.37(<0.0001) |
| 12-month/LT ratio, % SE | 53.92 (4.08) | 52.50 (5.16) | 49.33 (4.64) | 0.97 (0.62-1.52) | 0.90 (0.59-1.38) |
| Wald χ21 (*p*) |  |  |  | 0.01 (0.9086) | 0.25 (0.6180) |
| Number of Past Year Episodes, *M* (SE) | 2.13 (0.17) | 2.31 (0.17) | 2.45 (0.22) | --- | --- |
| Wald *F*1 (*p*) |  |  |  | 0.22 (0.6403) | 9.52 (0.0038) |
| Number of Lifetime Episodes, *M* (SE) | 6.86 (0.73) | 4.90 (0.66) | 7.43 (2.38) | --- | --- |
| Wald *F*1 (*p*) |  |  |  | 0.03 (0.8591) | 39.39 (<0.0001) |
| Longest Lifetime Episode (months), *M* (SE) | 43.37 (6.31) | 3.45 (0.06) | 3.47 (0.05) | --- | --- |
| Wald *F*1 (*p*) |  |  |  | 38.65 (<0.0001) | 43.69 (<0.0001) |
| Time in Episode Since Onset (months), % SE | 65.72 (4.25) | 20.99 (1.80) | 22.39 (2.72) | --- | --- |
| Wald *F*1 (*p*) |  |  |  | 22929.40 (<0.0001) | 21349.80 (<0.0001) |

Note. GAD = generalized anxiety disorder; GAD-6mo = cases met DSM-IV/5 GAD criteria; GAD-3-5mo = duration was **≥**3 months and **<** 6

months; GAD-3-5mo/NOU = duration was **≥**3 months and **<** 6 months and uncontrollability criterion was not applied; adjusted odds ratios and 95% confidence intervals control for all significant sociodemographic predictors of GAD (sex, age, race).

**Supplementary Table S3. Associated Symptoms and Course Characteristics of Generalized Anxiety Disorder Among Threshold and Subthreshold Cases By Age Group**

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **GAD Definition** | | | | | | | | | | | |
|  | **GAD-6mo**  **n = 284** | | |  | **GAD-3mo**  **n = 463** | | |  | **GAD-3mo/NOU**  **n = 545** | | |  |
| **Age Group** | **13-14** | **15-16** | **17-18** | ***Wald***  ***χ2/F(2)***  ***p-value*** | **13-14** | **15-16** | **17-18** | ***Wald***  ***χ2/F(2)***  ***p-value*** | **13-14** | **15-16** | **17-18** | ***Wald***  ***χ2/F(2)***  ***p-value*** |
| **Associated Symptoms** |  |  |  |  |  |  |  |  |  |  |  |  |
| Restlessness, % SE | 55.34  5.66 | 76.00  5.70 | 71.88  3.15 | *4.93*  *0.0849* | 56.78  5.39 | 82.20  3.79 | 80.48  2.82 | *13.96*  *0.0009* | 57.50  5.77 | 81.46  3.89 | 77.44  2.65 | *9.32*  *0.0095* |
| Easily Fatigued, % SE | 61.04  5.06 | 52.89  4.76 | 57.75  5.53 | *0.45*  *0.7981* | 59.43  5.51 | 55.62  5.05 | 60.15  4.92 | *0.34*  *0.8396* | 53.45  7.29 | 55.65  5.18 | 63.69  5.14 | *1.52*  *0.4671* |
| Poor Concentration, %  SE | 83.41  3.57 | 80.63  4.05 | 87.86  3.74 | *1.23*  *0.5397* | 82.77  2.50 | 82.77  2.50 | 89.82  2.57 | *4.28*  *0.1174* | 72.69  8.66 | 82.70  2.37 | 90.90  2.38 | *5.94*  *0.0511* |
| Irritable, % SE | 65.25  4.95 | 70.87  5.70 | 75.68  5.84 | *0.75*  *0.6877* | 67.09  4.97 | 72.28  3.38 | 77.53  5.16 | *1.19 0.5522* | 66.05  5.39 | 71.21  3.05 | 76.08  4.28 | *1.13*  *0.5677* |
| Muscle Tension, % SE | 33.94  6.19 | 45.99  4.64 | 54.51  5.74 | *3.00*  *0.2233* | 35.32  4.10 | 48.96  4.39 | 49.63  3.75 | *3.41*  *0.1819* | 36.85  5.73 | 46.70  4.16 | 48.56  3.39 | *2.20*  *0.3332* |
| Sleep Disturbance, %  SE | 56.19  7.97 | 72.56  4.17 | 73.07  5.06 | *1.76*  *0.4158* | 63.72  5.26 | 69.06  4.11 | 75.77  3.96 | *2.03*  *0.3629* | 69.13  5.47 | 69.66  3.74 | 73.94  3.51 | *0.59*  *0.7436* |
| Only Restlessness or  Muscle Tension, % SE | 66.24  6.00 | 82.72  4.26 | 75.68  5.84 | *2.84*  *0.2407* | 68.20  4.38 | 87.24  2.79 | 83.91  2.70 | *12.47*  *0.0020* | 74.63  4.24 | 86.36  2.94 | 80.62  2.72 | *4.90*  *0.0864* |
| **Number of Symptoms** |  |  |  |  |  |  |  |  |  |  |  |  |
| One Symptom, % SE | 14.98  5.20 | 5.14  1.21 | 5.72  4.30 | *2.11*  *0.3478* | 10.69  3.70 | 4.16  1.07 | 3.66  2.85 | *2.83*  *0.2434* | 8.80  3.01 | 3.67  0.94 | 3.31  2.42 | *2.70*  *0.2590* |
| Two Symptoms, % SE | 12.14  2.47 | 12.76  4.34 | 11.77  3.18 | *0.03*  *0.9848* | 16.24  4.68 | 13.30  3.21 | 10.54  2.26 | *0.96*  *0.6186* | 12.71  3.80 | 15.91  3.40 | 13.73  2.15 | *0.28*  *0.8712* |
| Three Symptoms, % SE | 17.18  3.31 | 13.53  3.22 | 13.30  2.29 | *0.10*  *0.9525* | 18.98  3.23 | 13.39  3.95 | 13.13  3.30 | *0.57*  *0.7523* | 29.32  7.99 | 13.42  3.65 | 11.46  3.21 | *4.09*  *0.1292* |
| Four Symptoms, % SE | 28.19  9.25 | 35.04  7.67 | 19.00  3.25 | *3.31*  *0.1915* | 25.06  6.25 | 28.72  5.22 | 19.75  2.62 | *2.21*  *0.3318* | 23.08  5.39 | 26.40  4.95 | 19.26  2.41 | *1.59*  *0.4519* |
| Five Symptoms, % SE | 13.46  3.90 | 14.62  4.14 | 26.52  3.91 | *4.87*  *0.0875* | 14.73  3.79 | 18.16  3.60 | 27.97  3.52 | *4.42*  *0.1097* | 15.36  4.07 | 18.09  3.37 | 25.62  3.65 | *2.54*  *0.2812* |
| Six Symptoms, % SE | 14.05  7.12 | 18.91  3.00 | 23.69  3.30 | *0.92*  *0.6299* | 14.29  4.52 | 22.28  3.52 | 24.96  2.76 | *2.03*  *0.3629* | 10.72  3.89 | 22.50  3.67 | 26.62  3.36 | *5.47*  *0.0650* |
| Number of Symptoms, *M* (SE) | 3.55  (0.25) | 3.98  (0.20) | 4.19  (0.24) | *1.55*  *0.2242* | 3.60 (0.17) | 4.10  (0.14) | 4.33 (0.19) | *3.42*  *0.0421* | 3.56  (0.15) | 4.07 (0.13) | 4.30  (0.18) | *4.83*  *0.0130* |
| **Course Characteristics** |  |  |  |  |  |  |  |  |  |  |  |  |
| Age At Onset (years),  *Md* (SE) | 9.76 (0.38) | 11.83  (0.42) | 12.98  (0.52) | *25179.49*  *<0.0001* | 10.07  (0.36) | 12.23  (0.22) | 12.83  (0.36) | *74540.23*  *<0.0001* | 9.58  (1.02) | 12.41  (0.25) | 12.74  (0.26) | *114932.19*  *<0.0001* |
| 12-month/LT ratio, %  SE | 59.62  8.31 | 45.11  5.13 | 65.13  4.64 | *5.95*  *0.0511* | 57.97  6.13 | 47.60  5.80 | 60.05  4.12 | *2.57*  *0.2772* | 46.02  7.19 | 47.99  5.51 | 56.42  3.62 | *1.41*  *0.4931* |
| Number of Past Year  Episodes, *M* (SE) | 2.44  (0.58) | 1.95  (0.24) | 2.16  (0.18) | *35.31*  *<.0001* | 2.45  (0.35) | 2.21  (0.18) | 2.05  (0.12) | *8.11*  *0.0011* | 2.53  (0.31) | 2.50  (0.24) | 2.02  (0.11) | *16.72*  *<0.0001* |
| Number of Lifetime  Episodes, *M* (SE) | 5.64  (1.34) | 6.00  (0.63) | 8.86  (1.69) | *1.46*  *0.2440* | 6.37  (1.26) | 5.12  (0.45) | 7.79  (1.38) | *2.00*  *0.1488* | 5.80  (0.89) | 7.17  (1.75) | 7.07  (1.18) | *0.42*  *0.6569* |
| Longest Lifetime  Episode (months), *M* (SE) | 56.00  (12.98) | 41.43  (8.96) | 40.03  (8.30) | *0.64*  *0.5333* | 30.40  (8.76) | 26.69  (6.44) | 26.91  (5.46) | *0.08*  *0.9264* | 34.72  (9.42) | 24.91  (5.85) | 26.64  (4.80) | *0.40*  *0.6733* |
| Time in Episode Since Onset (months), % SE | 77.59  6.92 | 64.59  5.28 | 62.69  5.71 | *2.06*  *0.1410* | 51.16  6.25 | 49.36  5.08 | 47.77  5.22 | *0.10*  *0.9046* | 57.51  9.53 | 49.69  4.81 | 44.71  4.48 | *0.96*  *0.3917* |

Note. GAD = generalized anxiety disorder; GAD-6mo = cases met DSM-IV/5 GAD criteria; GAD-3mo = duration was relaxed to at least 3 months; GAD-3mo/NOU = duration was relaxed to at least 3 months and uncontrollability criterion was not applied; a reports based on parent self-administered questionnaire sample (n = 6,483).

**Supplementary Tables S4. Severity and Impairment of Threshold and Subthreshold Generalized Anxiety Disorder**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | **GAD Definition** | | | | | |
|  | **GAD-6mo**  **n = 284** | **GAD-3mo**  **n = 463** | **GAD-3mo/**  **NOU**  **n = 545** | **GAD-6mo**  **vs.**  **Unaffected** | **GAD-3mo**  **vs.**  **Unaffected** | **GAD-3mo/NOU**  **vs.**  **Unaffected** |
| **Severity and Impairment** |  |  |  |  |  |  |
| Severe Cases, % SE | 42.04 (4.25) | 39.49 (3.60) | 35.65 (2.83) |  |  |  |
| Wald χ21 (*p*) |  |  |  | 35.24 (<0.0001) | 59.93 (<0.0001) | 57.62 (<0.0001) |
| Past Year Impairment, *M* (SE) | 6.94 (0.21) | 6.76 (0.26) | 6.81 0.25 |  |  |  |
| Wald  *F*1 (*p*) |  |  |  | 133.31 (<0.0001) | 649.99 (<0.0001) | 358.38 (<0.0001) |
| Days Out of Role, *M* (SE) | 7.37 (1.60) | 7.69 (1.42) | 7.55 1.49 |  |  |  |
| Wald  *F*1 (*p*) |  |  |  | 0.10 (0.7539) | 54.49 (<0.0001) | 196.68 (<0.0001) |
| GAD Treatment Contact, % SE | 37.25 (3.37) | 31.32 (2.45) | 27.77 2.38 |  |  |  |
| Wald χ21 (*p*) |  |  |  | 69.42 (<0.0001) | 127.08 (<0.0001) | 145.73 (<0.0001) |
| Anxiety Treatment Contact, % SE | 26.13 (2.75) | 22.58 (2.27) | 22.01 1.95 |  |  |  |
| Wald χ21 (*p*) |  |  |  | 4.33 (0.0375) | 6.79 (0.0092) | 6.26 (0.0124) |
| Any Lifetime Treatment, % SE | 53.69 (3.74) | 50.69 (3.26) | 49.34 3.17 |  |  |  |
| Wald χ21 (*p*) |  |  |  | 9.23 (0.0024) | 18.19 (<0.0001) | 18.50 (<0.0001) |

Note. GAD = generalized anxiety disorder; GAD-6mo = cases met DSM-IV/5 GAD criteria; GAD-3mo = duration was relaxed to at least 3 months; GAD-3mo/NOU = duration was relaxed to at least 3 months and uncontrollability criterion was not applied; regression models controlled for all significant sociodemographic predictors (sex, age, race) and other psychiatric disorders (but the disorder of interest).

**Supplementary Table S5. Associations of Anxiety Disorder Mutually Exclusive Groups With Other Mental Disorders**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **GAD Mutually Exclusive Definition** | | | **Comparisons of**  **Mutually Exclusive GAD Groups** | |
|  | **Weighted Proportion % SE** | | | **Adjusted Odds Ratio**  **(95% C.I.)** | |
| **Mental Disorders** | **GAD-6mo**  **n = 284** | **GAD-3-5mo**  **n = 179** | **GAD-3-5mo/**  **NOU**  **n = 214** | **GAD-3-5mo**  **vs.**  **GAD-6** | **GAD-3-5mo/**  **NOU**  **vs.**  **GAD-6** |
| Any Anxiety Disorder, % (SE) | 65.80 (4.83) | 61.95 (2.89) | 58.85 (3.13) | 0.56 (0.31-1.03) | 0.55 (0.31-0.98) |
| Wald χ21 (p) |  |  |  | 3.48 (0.0620) | 4.09 (0.0432) |
| Specific Phobia, % (SE) | 40.71 (2.81) | 25.23 (4.05) | 24.25 (3.51) | 0.69 (0.30-1.60) | 0.61 (0.28-1.32) |
| Wald χ21 (p) |  |  |  | 0.76 (0.3839) | 1.58 (0.2086) |
| Social Phobia, % (SE) | 20.08 (3.74) | 23.88 (3.50) | 20.22 (3.27) | 1.33 (0.60-2.94) | 1.02 (0.46-2.27) |
| Wald χ21 (*p*) |  |  |  | 0.49 0.4857 | 0.00 (0.9626) |
| Agoraphobia, % (SE) | 10.94(2.58) | 9.17 (3.68) | 7.55 (3.13) | 1.00 (0.32-3.14) | 0.83 (0.27-2.54) |
| Wald χ21 (*p*) |  |  |  | 0.00 (0.9956) | 0.10 (0.7467) |
| Panic Disorder, % (SE) | 10.12 (2.37) | 9.00 (2.32) | 9.41 (2.41) | 1.34 (0.44-4.07) | 1.54 (0.54-4.40) |
| Wald χ21 (*p*) |  |  |  | 0.26 (0.6094) | 0.64 (0.4242) |
| Separation Anxiety Disorder, % (SE) | 20.95 (4.01) | 22.63 (3.68) | 22.97 (3.60) | 0.88 (0.39-1.99) | 0.99 (0.48-2.02) |
| Wald χ21 (*p*) |  |  |  | 0.10 (0.7558) | 0.00 (0.9752) |
| PTSD, % (SE) | 20.59 (4.21) | 18.35 (4.49) | 15.89 (4.02) | 0.26 (0.08-0.84) | 0.21 (0.07-0.61) |
| Wald χ21 (*p*) |  |  |  | 5.06 (0.0245) | 8.16 (0.0043) |
| Any Mood Disorder, % (SE) | 58.55 (4.31) | 47.15 (4.41) | 46.15 (4.40) | 1.13 (0.52-2.45) | 1.15 (0.53-2.48) |
| Wald χ21 (*p*) |  |  |  | 0.09 (0.7618) | 0.13 (0.7213) |
| Major Depression, % (SE) | 54.41 (4.51) | 39.04 (3.85) | 38.86 (4.26) | 0.99 (0.49-1.98) | 0.99 (0.49-2.03) |
| Wald χ21 (*p*) |  |  |  | 0.01 (0.9718) | 0.00 (0.9866) |
| Dysthymia, % (SE) | 22.61 (3.76) | 9.66 (2.47) | 10.65 (3.05) | 0.23 (0.08-0.71) | 0.32 (0.14-0.78) |
| Wald χ21 (*p*) |  |  |  | 6.59 (0.0103) | 6.52 (0.0106) |
| Bipolar Disorder, % (SE) | 7.94 (1.71) | 13.82 (3.89) | 13.95 (3.80) | 8.58 (2.56-28.84) | 9.55 (2.69-33.87) |
| Wald χ21 (*p*) |  |  |  | 12.09 (0.0005) | 12.19 (0.0005) |
| Any Behavior Disordera, % (SE) | 29.89 (3.97) | 24.76 (3.89) | 32.14 (3.95) | 0.76 (0.32-1.82) | 0.71 (0.33-1.52) |
| Wald χ21 (*p*) |  |  |  | 0.39 (0.5342) | 0.80 (0.3721) |
| ODDa, % (SE) | 22.88 (4.52) | 13.86 (2.95) | 15.51 (4.11) | 0.38 (0.08-1.66) | 0.43 (0.12-1.57) |
| Wald χ21 (*p*) |  |  |  | 1.65 (0.1988) | 1.64 (0.1998) |
| Conduct Disordera, % (SE) | 21.12 (3.68) | 20.53 (4.20) | 20.60 (2.83) | 2.04 (0.69-6.02) | 1.85 (0.67-5.16) |
| Wald χ21 (*p*) |  |  |  | 1.66 (0.1972) | 1.39 (0.2377) |
| ADHDa, % (SE) | 16.78 (2.88) | 12.68 (3.57) | 15.57 (2.77) | 0.39 (0.15-1.02) | 0.44 (0.20-0.94) |
| Wald χ21 (*p*) |  |  |  | 3.72 (0.0537) | 4.45 (0.0349) |
| Any Substance Use Disorder, % (SE) | 23.61 (3.83) | 22.23 (4.23) | 21.29 (4.23) | 0.35 (0.10-1.21) | 0.43 (0.13-1.40) |
| Wald χ21 (*p*) |  |  |  | 2.74 (0.0982) | 1.97 (0.1599) |
| Alcohol Use Disorders, % (SE) | 14.58 (3.16) | 19.30 (4.18) | 15.96 (3.72) | 0.75 (0.27-2.09) | 0.53 (0.19-1.46) |
| Wald χ21 (*p*) |  |  |  | 0.30 (0.5840) | 1.51 (0.2190) |
| Drug Use Disorders, % (SE) | 17.26 (3.02) | 19.75 (3.83) | 19.18 (4.01) | 0.48 (0.13-1.77) | 0.61 (0.16-2.28) |
| Wald χ21 (*p*) |  |  |  | 1.23 (0.2679) | 0.54 (0.4625) |

Note. GAD = generalized anxiety disorder; PTSD = posttraumatic stress disorder, ODD = oppositional defiant disorder, ADHD =

attention deficit/hyperactivity disorder; CI = confidence interval; adjusted odds ratios and 95% confidence intervals include all

significant sociodemographic predictors (sex, age, race) and other psychiatric disorders (but the disorder of interest); a reports based on

parent self-administered questionnaire sample (n = 6,483); GAD-6mo = cases met DSM-IV/5 GAD criteria; GAD-3-5mo = duration was **≥**3 months

and **<** 6 months; GAD-3-5mo/NOU = duration was **≥**3 months and **<** 6 months and uncontrollability criterion was not applied.